Streptococcus salivarius -derived ilexgenin A alleviates pneumonia through the gut-lung axis
mSystems · 2025
DOI: 10.1128/msystems.00731-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSystems, 2025. Verfasst von Xintao Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Clinical Pharmacy, Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Streptococcus, Pneumonia, Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
The alteration of gut microbiota during critical illness is associated with adverse clinical outcomes. This connection between intestinal dysbiosis and poor outcomes has prompted the idea that restoring healthy microbial communities could offer a novel approach to life-support treatment for patients with severe pneumonia. In this study, using 16S rRNA sequencing and fecal microbiota transplantation (FMT), we demonstrated that alterations in intestinal microbiota structure during pneumonia exacerbate disease outcomes. A notable feature of these alterations is the reduction in the relative levels of Streptococcus salivarius ( S. salivarius ). In combination with metabolomics analysis, we found that the administration of S. salivarius increased the level of ilexgenin A (IA) in mice, which enhances the resistance of mice to Pseudomonas aeruginosa ( P. aeruginosa )-induced pneumonia. Mechanistically, IA regulates lipopolysaccharide-induced overexpression of macrophage inflammation through Toll-like receptor 4 (TLR4)-mediated NF-κB and MAPK signaling pathways. Our findings reveal the role of the microbial–immune axis in pneumonia, highlighting the potential of S. salivarius and IA in providing promising treatment strategies for pneumonia. IMPORTANCE One of the major challenges faced by the clinical microbiome research community is to convert the connections between dysbiosis and negative clinical outcomes into rationalized and targeted therapeutic interventions. In the present work, 30 fecal samples from pneumonia and non-pneumonia patients were subjected to FMT and 16S rRNA analysis. The results revealed that a characteristic feature of gut microbiota dysbiosis in pneumonia hosts is the reduction of S. salivarius . Supplementation with S. salivarius can effectively enhance the resistance of mice to P. aeruginosa pneumonia. Moreover, we confirmed the anti-inflammatory effects of IA derived from S. salivarius both in vivo and in vitro . Thus, these findings enhance our understanding of how gut microbiota influences the outcomes of pneumonia and underscore the potential of S. salivarius as a precision microbial therapeutic for combating pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Clinical Pharmacy, Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
- The Tenth Affiliated Hospital (Dongguan People's Hospital), Shenzhen Clinical Medical School, Southern Medical University, Dongguan, Guangzhou, China.
- Center for Drug Research and Development, Guangdong Provincial Key Laboratory of Advanced Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou, China.
- Department of Critical Care Medicine, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
ORCID-Profile: Rong Wu, Zhengzheng Yan, Wei Xiao, Yun Ma
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Huang, X., Wu, R., Liang, X., Yu, Z., Qin, P., Wang, Z., Guo, P., Zeng, Y., Yan, Z., Xiao, W., & Ma, Y. (2025). Streptococcus salivarius -derived ilexgenin A alleviates pneumonia through the gut-lung axis. mSystems. https://doi.org/10.1128/msystems.00731-25
Vancouver
Huang X, Wu R, Liang X, Yu Z, Qin P, Wang Z, et al. Streptococcus salivarius -derived ilexgenin A alleviates pneumonia through the gut-lung axis. mSystems. 2025. doi:10.1128/msystems.00731-25
BibTeX
@article{Huang2025,
author = {Huang, Xintao and Wu, Rong and Liang, Xiaoqi and Yu, Zhichao and Qin, Ping and Wang, Ze and Guo, Peiheng and Zeng, Yunong and Yan, Zhengzheng and Xiao, Wei and Ma, Yun},
title = {Streptococcus salivarius -derived ilexgenin A alleviates pneumonia through the gut-lung axis},
journal = {mSystems},
year = {2025},
doi = {10.1128/msystems.00731-25}
}
EUVIMED